Target-based drug discovery and cancer treatment
One topic in cancer biology that continues to grow in importance for graduate students training in cancer research is the area of novel approaches in cancer treatment and cancer drug discovery. As the number of signal transduction target-based anticancer drugs that have entered the clinic has increased, with many more in the pipeline, it has become apparent that most trainees in basic cancer research are lacking in their understanding of many issues involving cancer treatment and drug development.
The course is offered every other year. The course topics for the this semester are as follows:
- Conventional cancer chemotherapy
- Target identification and validation
- Identification of hits - high-throughput screening, rational drug desing, lead identification
- Lead compound evaluation- in vitro to cell-based assays
- Lead compound evaluation - preclinical animal studies
- Clinical trials– design and implementation
- Role of academia, industry, and government
- State of the art– what is in the pipeline?
The course is coordinated by Drs. Adrienne Cox and Channing Der. They have served as consultants for the drug discovery programs of various pharmaceutical companies, and target-based drug discovery is an essential and significant component of their research programs. Their research is funded in part by a National Cooperative Drug Discovery Grant from the NIH. Dr. Cox’s research studies involve the study of target-based anti-cancer drugs and the study of radiation damage.
Links to the core curriculum of five required courses:
GNET 621 and GNET 631: Advanced Molecular Biology I & II
CBIO 644: Cell Structure, Function and Growth Control II (Super Cell)
PATH 725: Cancer Pathobiology
PHCO 737: Target-based drug discovery and cancer treatment
